These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 18198933)

  • 1. Modelling methods for pharmacoeconomics and health technology assessment: an overview and guide.
    Stahl JE
    Pharmacoeconomics; 2008; 26(2):131-48. PubMed ID: 18198933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rates and probabilities in economic modelling: transformation, translation and appropriate application.
    Fleurence RL; Hollenbeak CS
    Pharmacoeconomics; 2007; 25(1):3-6. PubMed ID: 17192114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of pharmacoeconomics in prescribing research. Part 5: modelling--beyond clinical trials.
    Lang DL; Lopert R; Hill SR
    J Clin Pharm Ther; 2003 Oct; 28(5):433-9. PubMed ID: 14632969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What you don't know can't hurt you? Statistical issues and standards for medical technology evaluation.
    Mullahy J
    Med Care; 1996 Dec; 34(12 Suppl):DS124-35. PubMed ID: 8969321
    [No Abstract]   [Full Text] [Related]  

  • 5. Verification of Decision-Analytic Models for Health Economic Evaluations: An Overview.
    Dasbach EJ; Elbasha EH
    Pharmacoeconomics; 2017 Jul; 35(7):673-683. PubMed ID: 28456972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modelling in the economic evaluation of health care: selecting the appropriate approach.
    Barton P; Bryan S; Robinson S
    J Health Serv Res Policy; 2004 Apr; 9(2):110-8. PubMed ID: 15099459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incorporation of statistical uncertainty in health economic modelling studies using second-order Monte Carlo simulations.
    Nuijten MJ
    Pharmacoeconomics; 2004; 22(12):759-69. PubMed ID: 15294010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining types of economic evaluation.
    Ngorsuraches S
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S21-7. PubMed ID: 19255985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Methods for analyzing uncertainty].
    Ferriols R; Alós M
    Farm Hosp; 2011 May; 35 Suppl 2():3-9. PubMed ID: 22445503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Discrete-event simulation models in the economic evaluation of health technologies and health products].
    Rodríguez Barrios JM; Serrano D; Monleón T; Caro J
    Gac Sanit; 2008; 22(2):151-61. PubMed ID: 18420015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methods for determining cost-benefit ratios for pharmaceuticals in Germany.
    von der Schulenburg J; Vauth C; Mittendorf T; Greiner W
    Eur J Health Econ; 2007 Sep; 8 Suppl 1():S5-31. PubMed ID: 17582539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A taxonomy of model structures for economic evaluation of health technologies.
    Brennan A; Chick SE; Davies R
    Health Econ; 2006 Dec; 15(12):1295-310. PubMed ID: 16941543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overview of pharmacoeconomic modelling methods.
    Ademi Z; Kim H; Zomer E; Reid CM; Hollingsworth B; Liew D
    Br J Clin Pharmacol; 2013 Apr; 75(4):944-50. PubMed ID: 22882459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An introduction to Markov modelling for economic evaluation.
    Briggs A; Sculpher M
    Pharmacoeconomics; 1998 Apr; 13(4):397-409. PubMed ID: 10178664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incorporation of uncertainty in health economic modelling studies.
    Nuijten M
    Pharmacoeconomics; 2005; 23(8):851-3; author reply 853. PubMed ID: 16097845
    [No Abstract]   [Full Text] [Related]  

  • 16. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra.
    Claxton K; Sculpher M; McCabe C; Briggs A; Akehurst R; Buxton M; Brazier J; O'Hagan T
    Health Econ; 2005 Apr; 14(4):339-47. PubMed ID: 15736142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling Treatment Sequences in Pharmacoeconomic Models.
    Zheng Y; Pan F; Sorensen S
    Pharmacoeconomics; 2017 Jan; 35(1):15-24. PubMed ID: 27722894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Indirect costs in health technology assessment].
    Jakubczyk M; Wrona W; Macioch T; Golicki D; Niewada M; Hermanowski T
    Pol Merkur Lekarski; 2010 Jan; 28(163):42-5. PubMed ID: 20369723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regarding probabilistic analysis and computationally expensive models: necessary and required?
    Caro JJ; Getsios D; Möller J
    Value Health; 2007; 10(4):317-8; author reply 319. PubMed ID: 17645686
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacoeconomic analyses using discrete event simulation.
    Caro JJ
    Pharmacoeconomics; 2005; 23(4):323-32. PubMed ID: 15853433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.